alendronate has been researched along with Kidney Failure, Chronic in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia." | 7.74 | Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007) |
| "We describe a case of collapsing focal segmental glomerulosclerosis and severe kidney dysfunction in a liver transplant recipient after the initiation of alendronate for osteopenia." | 3.74 | Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. ( Djamali, A; Musat, A; Myers, J; Pascual, J; Samaniego, M; Tome, S; Torrealba, J, 2007) |
| " We calculated the standard mean deviations with 95% confidence intervals (CI) for bone mineral density (BMD) and T scores after 6 and 12 months treatment, pooled odds ratio and 95% CI for fracture risk, and summarized adverse events." | 3.01 | Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. ( Leng, Y; Xia, Y; Yang, Y; Yu, X, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Leng, Y | 1 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Xia, Y | 1 |
| Neves, JM | 1 |
| Cabete, J | 1 |
| Fernandes, C | 1 |
| Etemadi, J | 1 |
| Bagheri, N | 1 |
| Falaknazi, K | 1 |
| Ardalan, M | 1 |
| Rahbar, K | 1 |
| Nobakht Haghighi, A | 1 |
| Mohajel Shoja, M | 1 |
| Toussaint, ND | 1 |
| Lau, KK | 1 |
| Strauss, BJ | 1 |
| Polkinghorne, KR | 1 |
| Kerr, PG | 1 |
| Abediazar, S | 1 |
| Nakhjavani, MR | 1 |
| Pascual, J | 1 |
| Torrealba, J | 1 |
| Myers, J | 1 |
| Tome, S | 1 |
| Samaniego, M | 1 |
| Musat, A | 1 |
| Djamali, A | 1 |
| Yee, J | 1 |
1 review available for alendronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; | 2023 |
1 trial available for alendronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
Topics: Aged; Alendronate; Aorta; Calcinosis; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Middle | 2010 |
5 other studies available for alendronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Nonuraemic cutaneous calciphylaxis: our experience with a challenging disease.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation | 2020 |
Paget's disease of bone in a patient on hemodialysis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Female; Humans; Kidney Fa | 2008 |
Effect of alendronate on early bone loss of renal transplant recipients.
Topics: Adult; Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2011 |
Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glomerulosclerosis, Focal S | 2007 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |